Hairy cell leukemia: Update and current therapeutic approach Review uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Imidazoles
  • Indoles
  • Leukemia, Hairy Cell
  • Oximes
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins B-raf
  • Sulfonamides

abstract

  • Identification of the BRAFV600E mutation in nearly 100% of HCL patients has provided rationale for inclusion of BRAF inhibitors into the therapeutic armamentarium to treat HCL. Clinical trials are currently underway measuring efficacy of vemurafenib in achieving clinical response in relapsed/refractory HCL and also toxicity. Other novel therapies with monoclonal and immunotoxin-conjugated antibodies have also shown promising response in recent investigational studies.

publication date

  • January 2015

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1097/MOH.0000000000000154

PubMed ID

  • 26049757

Additional Document Info

start page

  • 355

end page

  • 61

volume

  • 22

number

  • 4